Blog

Perspectives in Breast and Colorectal Cancer Research


NSABP Foundation

Dr. Charles Geyer discusses the NSABP B-59/GBG 96-GeparDouze trial

Charles Geyer, MD, Associate Director of Clinical Research at the VCU Massey Cancer Center

Charles Geyer, MD, Associate Director of Clinical Research at the Virginia Commonwealth University Massey Cancer Center and NSABP Principal Investigator discusses immunotherapy and checkpoint inhibitors for breast cancer studies including the NSABP B-59/GBG 96-GeparDouze clinical trial.

Previous Article Peter Lucas, MD, discusses the use of correlative science post-clinical trials
Next Article Dr. Charles Geyer discusses the KATHERINE Trial with Dr. Jame Abraham
Print
3350

Name:
Email:
Subject:
Message:
x